Skip to main content
SPRB logo

SPRB · Spruce Biosciences, Inc.

$42.28 -2.71 (-6.02%) At close · Jul 24
Market Cap
$118.57M
Shares
2.75M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$0 -100%
FY2025 Revenue FY2022–FY2025
Net Income
-$38.97M +26.5%
FY2025 Net Income FY2019–FY2025
Operating Margin
-1143.37% -628pp
FY2024 Operating Margin FY2023–FY2024
Diluted EPS
-$50.83 +47.3%
FY2025 Diluted EPS FY2021–FY2025
Operating Cash Flow
-$33.33M +40.4%
FY2025 Operating Cash Flow FY2019–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
$0 $4.91M $10.09M $0
$16.26M $19.52M $46.42M $49.43M $35.2M $30.7M $23.85M $10.82M
$17.75M $16.99M $14.64M $12.65M $12.09M $11.37M $5.56M $2.29M
$21K $46K $70K $74K $68K $36K $12K
$34.01M $36.51M $61.06M $62.08M $47.28M $42.07M $29.42M $13.11M
-$34.01M -$36.51M -$56.15M -$51.99M -$47.28M -$42.07M -$29.42M -$13.11M
-1143.37% -515.34%
-$36.49M -$56.11M -$51.92M -$47.21M -$42M -$29.38M -$13.1M
$728K $90K $307K $483K $420K $345K $323K $65K
$119K $200K $84K
$0 $0 $0 $0 $0 $0 $0
-$37.19M -$38.97M -$53.04M -$47.92M -$46.18M -$42.29M -$29.54M -$13.09M
-1079.94% -474.96%
-$53.04M -$47.36M -$46.55M -$42.48M -$29.54M
USD/shares -$50.83 -$96.40 -$6,975.00 -$11,025.00 -$10,181.25
USD/shares -$50.83 -$96.40 -$6,975.00 -$11,025.00 -$10,181.25
shares 766.6K 550.15K 6846.2613 4182.5984 4153.1406 1065.1045 135.8948
shares 766.6K 550.15K 6846.2613 4182.5984 4153.1406 1065.1045 135.8948
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Biotechnology median 8.41×
EV/EBIT
Biotechnology median 26.60×
P/E (TTM)
Biotechnology median 7.07×

Valuation over time computed as of each quarter's filing date

Key facts CIK 1683553 CUSIP 85209E208 13F (30d) 3 filings 3 filers Visit website Investor relations